FI955351L - Tarttumisreseptoriantagonistit - Google Patents

Tarttumisreseptoriantagonistit Download PDF

Info

Publication number
FI955351L
FI955351L FI955351A FI955351A FI955351L FI 955351 L FI955351 L FI 955351L FI 955351 A FI955351 A FI 955351A FI 955351 A FI955351 A FI 955351A FI 955351 L FI955351 L FI 955351L
Authority
FI
Finland
Prior art keywords
receptor antagonists
adhesion receptor
adhesion
antagonists
receptor
Prior art date
Application number
FI955351A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI955351A0 (fi
FI955351A7 (fi
Inventor
Joachim Gante
Horst Juraszyk
Peter Raddatz
Hanns Wurziger
Sabine Bernotat-Danielowski
Guido Melzer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of FI955351A0 publication Critical patent/FI955351A0/fi
Publication of FI955351L publication Critical patent/FI955351L/fi
Publication of FI955351A7 publication Critical patent/FI955351A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
FI955351A 1994-11-08 1995-11-07 Tarttumisreseptoriantagonistit FI955351A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4439846A DE4439846A1 (de) 1994-11-08 1994-11-08 Adhäsionsrezeptor-Antagonisten

Publications (3)

Publication Number Publication Date
FI955351A0 FI955351A0 (fi) 1995-11-07
FI955351L true FI955351L (fi) 1996-05-09
FI955351A7 FI955351A7 (fi) 1996-05-09

Family

ID=6532768

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955351A FI955351A7 (fi) 1994-11-08 1995-11-07 Tarttumisreseptoriantagonistit

Country Status (22)

Country Link
US (1) US5776937A (cs)
EP (1) EP0711770A1 (cs)
JP (1) JPH08208629A (cs)
KR (1) KR100384978B1 (cs)
CN (1) CN1069640C (cs)
AR (1) AR002245A1 (cs)
AU (1) AU704184B2 (cs)
BR (1) BR9505109A (cs)
CA (1) CA2162223A1 (cs)
CO (1) CO4520229A1 (cs)
CZ (1) CZ291049B6 (cs)
DE (1) DE4439846A1 (cs)
FI (1) FI955351A7 (cs)
HU (1) HU217085B (cs)
NO (1) NO306113B1 (cs)
PL (1) PL183595B1 (cs)
RU (1) RU2155762C2 (cs)
SK (1) SK281815B6 (cs)
TR (1) TR199501389A2 (cs)
TW (1) TW316903B (cs)
UA (1) UA41928C2 (cs)
ZA (1) ZA959434B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DK0710657T3 (da) * 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
EA200100573A1 (ru) 1998-12-23 2002-02-28 Дж.Д.Сирл Энд Ко. Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
EP1147422A1 (en) 1999-01-27 2001-10-24 Pharmacia & Upjohn Company Assays for modulators of "elongation factor p" activity
WO2003061715A1 (en) * 2002-01-22 2003-07-31 Pharmacia & Upjohn Company Infection-resistant medical devices
AU2003275480A1 (en) * 2002-10-07 2004-05-04 Smithkline Beecham Corporation Compounds
BR0317671A (pt) * 2002-12-24 2005-11-29 Sankyo Co Composto
CN102796091A (zh) * 2011-05-24 2012-11-28 北大方正集团有限公司 取代的噁唑烷酮化合物及其制备方法和应用
JP6216385B2 (ja) * 2012-10-29 2017-10-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 3,4−二置換オキサゾリジノン誘導体及びカルシウム活性化カリウムチャネルの阻害薬としてのそれらの使用
CN104230915B (zh) * 2014-08-29 2016-08-17 南京大学 含噻唑烷二酮的苯基哌嗪衍生物及其制备方法与用途
CN117100751A (zh) 2017-06-20 2023-11-24 安布里亚制药公司 用于提高心脏代谢效率的组合物和方法
EP3866794B1 (en) 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
DK0623615T3 (da) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE4405633A1 (de) * 1993-05-01 1994-11-03 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III

Also Published As

Publication number Publication date
KR960017663A (ko) 1996-06-17
UA41928C2 (uk) 2001-10-15
NO306113B1 (no) 1999-09-20
HU217085B (hu) 1999-11-29
ZA959434B (en) 1996-05-15
US5776937A (en) 1998-07-07
FI955351A0 (fi) 1995-11-07
PL183595B1 (pl) 2002-06-28
JPH08208629A (ja) 1996-08-13
NO954458D0 (no) 1995-11-07
AU704184B2 (en) 1999-04-15
RU2155762C2 (ru) 2000-09-10
CO4520229A1 (es) 1997-10-15
AU3661895A (en) 1996-05-23
AR002245A1 (es) 1998-03-11
CN1069640C (zh) 2001-08-15
BR9505109A (pt) 1997-09-09
EP0711770A1 (de) 1996-05-15
CZ288895A3 (en) 1996-06-12
TW316903B (cs) 1997-10-01
CA2162223A1 (en) 1996-05-09
PL311257A1 (en) 1996-05-13
HU9503191D0 (en) 1996-01-29
SK136895A3 (en) 1996-06-05
FI955351A7 (fi) 1996-05-09
NO954458L (no) 1996-05-09
SK281815B6 (sk) 2001-08-06
HUT76052A (en) 1997-06-30
CN1132201A (zh) 1996-10-02
DE4439846A1 (de) 1996-05-09
CZ291049B6 (cs) 2002-12-11
TR199501389A2 (tr) 1996-07-21
KR100384978B1 (ko) 2003-09-02

Similar Documents

Publication Publication Date Title
FI955223A7 (fi) Adheesioreseptoriantagonisteja
NO972016D0 (no) Indolyl-Y-reseptorantagonister
DE69734833D1 (de) Vitronektin rezeptor antagonisten
ATE258548T1 (de) Adhäsionsrezeptor-antagonisten
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
BR9508178A (pt) Antagonistas de receptor de vitronectina
DK1009732T3 (da) 1-Amino-alkylcyclohexan NMDA receptor antagonister
EP0986385A4 (en) GONADORELIN ANTAGONISTS
FI960953A7 (fi) Endoteliinireseptoriantagonisteja
EP0866705A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
NO950606D0 (no) Adhesjonsreseptor-antagonister
EP0810994A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
ID16742A (id) Antagonis reseptor endotelin
FI960516A7 (fi) Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja
ID24726A (id) Antagonis-antagonis reseptor trombin
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
FI955351L (fi) Tarttumisreseptoriantagonistit
ID24162A (id) Antagonis-antagonis reseptor vitronektin
BR9507220A (pt) Antagonistas de receptores de endotelina
EP0929218A4 (en) P2Y RECEPTOR ANTAGONISTS
DE69616364D1 (de) Endothelinrezeptorantagonisten
DE69636597D1 (de) Endothelin rezeptor antagonisten
ZA961159B (en) Adhesion receptor antagonists
DE59503324D1 (de) Adhäsionsrezeptor-Antagonisten
FI972558L (fi) Uusi reseptori

Legal Events

Date Code Title Description
MA Patent expired